Atossa Genetics Announces Third Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Atossa Genetics Announces Third Quarter 2015 Financial Results and Provides Company Update

SEATTLE, WA--(Marketwired - Nov 12, 2015) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) today announced third quarter 2015 financial results and provided an update on recent company developments. 

Dr. Steven C. Quay, Chairman, CEO & President, commented, "We are very pleased with our ongoing progress in establishing our two Phase II pharmaceutical clinical programs, topical Afimoxifene Gel and intraductal Fulvestrant, both of which have extensive patent portfolios. Today we are announcing that the National Cancer Institute has approved protocol development for a study to be funded by them using Afimoxifene Gel in their Cancer Prevention Clinical Trials Program. With respect to intraductal Fulvestrant, we are on track to commence the study in women with ductal carcinoma in situ, or DCIS, during December 2015."

Dr. Quay added, "We are taking a number of steps to address recent adverse changes in Medicare reimbursement for our pharmacogenomics test and to improve our pharmacogenomics test revenue, including the recent addition of additional sales personnel, targeting conditions and drugs that provide a higher rate of reimbursement, and enhancing sales incentives to drive sales volume."

Concluding, Dr. Quay commented, "We have much to look forward to in the last quarter of 2015 and into 2016. Our Phase II pharmaceutical development programs are expected to produce a number of value-creating milestones over the next six months for our shareholders."

Recent Corporate Developments 

Important recent corporate developments include the following:

  • Announced today that the National Cancer Institute, Division of Cancer Prevention, has approved a Letter of Intent submitted by a member of the Consortia for Cancer Prevention Clinical Trials Program for the study of Afimoxifene Gel in women with DCIS. The Consortia includes five major medical research centers: the University of Arizona, Northwestern University, Mayo Clinic Foundation, M. D. Anderson Cancer Center and the University of Wisconsin.
  • Held an advisory meeting in San Francisco with leading breast surgeons and oncologists and received advice on the clinical pathway and commercial opportunities for Afimoxifene Gel.
  • Announced FDA acceptance of our Investigational New Drug Application to begin a Phase II clinical trial of Fulvestrant for the potential treatment of DCIS and cancer using Atossa's patented intraductal microcatheter and patented methods of delivering pharmaceuticals.
  • Filed an application with the American Medical Association for a CPT code for the collection of nipple aspirate fluid at a doctor's office.
  • Signed manufacturing and quality agreements with AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. (AAI/CML) for the manufacturing of a clinical supply for 4-Hydroxytamoxifen, the active pharmaceutical ingredient in Afimoxifene Gel. 
  • Received approval to begin a clinical study in Israel to evaluate Atossa's ForeCYTE breast aspirator in the collection of nipple aspirate fluid.
  • Hired Janet Rose Rea, M.S.P.H. as VP Regulatory Affairs and Quality.
  • Atossa Genetics' laboratory received ISO 15189:2012 certification.
  • Promoted Scott Youmans to Chief Operating Officer.

Third Quarter 2015 Financial Results  

For the three months and nine months ended September 30, 2015, we had total net revenue of $772,244 and $5,339,669, respectively, consisting of pharmacogenomics testing, compared to $3,426 and $37,425 of revenue in the same periods in 2014, which consisted of additional cash collections on NAF cytology tests performed in 2013. Our pharmacogenomics test was launched in the fourth quarter of 2014 and we did not generate revenue in 2014 prior to that. In March 2015, we introduced the FullCYTE Breast Aspirator in the U.S. and the ForeCYTE Breast Aspirator in the EU; however, we have not generated any revenue in 2015 from sales of these products.

For the three months and nine months ended September 30, 2015, gross profit totaled $458,838 and $1,963,598, respectively, which was attributable to pharmacogenomics testing, compared to $3,426 and $37,425, in the same period in 2014. Total cost of revenue for the three months and nine months ended September 30, 2015 was $313,406 and $3,376,071, respectively, consisting of costs relating to pharmacogenomics testing services; there was no cost of revenue during the same periods in 2014 as the only revenue generated during those periods was from additional cash collections on NAF cytology tests performed in 2013.

For the three months ended September 30, 2015, total operating expenses were $4,846,294, consisting of general and administrative (G&A) expenses of $3,017,909, research and development (R&D) expenses of $1,090,349, and selling expenses of $738,036, representing an increase of $1,597,613, or 49% from $3,248,681 in the same period in 2014, consisting of G&A expenses of $2,043,138, R&D expenses of $923,169, and selling expenses of $282,374. Operating expenses for the nine months ended September 30, 2015 were $12,828,874 consisting of G&A expenses of $8,413,891, R&D expenses of $2,398,032, and selling expenses of $2,016,951. Operating expenses increased $3,948,736, or 44% from $8,880,138 for the same period in 2014 consisting of $6,280,102 in G&A expenses, $1,856,439 in R&D expenses, and $743,597 in selling expenses.

The increase in selling expenses is mainly due to increases in compensation expenses, travel, and advertisement as a result of the ForeCYTE and FullCYTE launch in Europe and the United States. We expect that our selling expenses will continue to increase during 2015, as we build a sales force in the United States to support primarily the services offered by the NRLBH, pharmacogenomics tests and potentially other tests.

G&A expenses consist primarily of personnel and related benefit costs, facilities, professional services, insurance, and public company related expenses. The increase in G&A expenses is mainly due to an increase in compensation expenses, professional fees, and recruiting fees as we increased our headcount to support the launch of our new products. The increase also reflects an increase in bad debt expenses as a result of significant increases in revenue and also higher than expected denials on non-Medicare appeals from prior periods.

We expect our G&A and selling expenses to continue to grow throughout 2015 as we hire additional administrative and manufacturing personnel to support the increased sales and operating activities as we promote, market and sell our pharmacogenomics testing and our other products and services under development.

The increase in R&D expenses is attributed to additional R&D expenditures on the launch and development of ForeCYTE and FullCYTE in the first quarter of 2015. We expect that our R&D expenditures will continue to grow as we develop our new products and tests in the pipeline, including Afimoxifene Gel, our intraductal microcatheters and our NextCYTE test and other laboratory tests we may develop. We will add additional full-time employees and incur additional costs to continue the development of our products and services under development, including the development of our potential pharmaceuticals and conducting clinical studies.

Conference Call Information

Management will host a conference call on Thursday, November 12, 2015 at 4:30 pm eastern time to review financial results and corporate highlights. Following management's formal remarks, there will be a question and answer session.

To listen to the call by phone, interested parties within the U.S. should call 1-866-652-5200 and International callers should call 1-412-317-6060. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com . Details for the webcast may be found on the Company's IR events page at http://ir.atossagenetics.com/ir-calendar .

A replay of the call will be available approximately one hour after the end of the call through December 12, 2015. The replay can be accessed via Atossa's website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll Free at 855-669-9658. The replay conference ID number is 10075755.

About Atossa Genetics

Atossa Genetics, Inc. is focused on improving breast health through the development of pharmaceuticals to treat breast health conditions and through the commercialization of medical devices and laboratory services. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health Inc. The laboratory's services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com .

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, including recalls of products, Atossa's ability to achieve its objectives, successfully complete clinical studies, continue to manufacture and sell its products, and the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward-looking statement.

   
   
ATOSSA GENETICS INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
   
    September 30,     December 31,  
    2015     2014  
    (Unaudited)        
Assets                
                 
Current assets                
  Cash and cash equivalents   $ 7,839,439     $ 8,500,718  
  Restricted cash     275,000       -  
  Accounts receivable, net     1,055,059       297,958  
  Prepaid expenses     201,652       247,207  
  Inventory, net     170,860       39,788  
    Total current assets     9,542,010       9,085,671  
                   
  Furniture and equipment, net     484,544       357,532  
  Intangible assets, net     1,768,812       1,920,645  
  Deferred financing costs     509,375       351,961  
  Other assets     52,649       48,193  
    Total assets   $ 12,357,390     $ 11,764,002  
                 
Liabilities and Stockholders' Equity                
                 
Current liabilities                
  Accounts payable   $ 1,179,329     $ 594,357  
  Accrued expenses     934,675       444,861  
  Payroll liabilities     1,156,000       1,056,705  
  Short-term lease obligations     -       76,025  
  Other current liabilities     22,601       42,228  
    Total current liabilities     3,292,605       2,214,176  
                   
  Deferred rent     5,688       2,483  
  Long-term lease obligations     -       49,216  
    Total liabilities     3,298,293       2,265,875  
                 
                 
Stockholders' equity                
  Preferred stock - $.001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding     -       -  
  Common stock - $.001 par value; 75,000,000 shares authorized, 30,446,260 and 24,564,058 shares issued and outstanding     30,446       24,564  
  Additional paid-in capital     55,001,918       44,648,103  
  Accumulated deficit     (45,973,267 )     (35,174,540 )
    Total stockholders' equity     9,059,097       9,498,127  
                 
  Total liabilities and stockholders' equity   $ 12,357,390     $ 11,764,002  
   
   
   
ATOSSA GENETICS INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(UNAUDITED)  
   
    For the Three Months Ended September 30,     For The Nine Months Ended September 30,  
    2015     2014     2015     2014  
Net revenue   $ 772,244     $ 3,426     $ 5,339,669     $ 37,425  
Cost of revenue     313,406       -       3,376,071       -  
    Gross profit     458,838       3,426       1,963,598       37,425  
Operating expenses:                                
  Selling     738,036       282,374       2,016,951       743,597  
  Research and development     1,090,349       923,169       2,398,032       1,856,439  
  General and administrative     3,017,909       2,043,138       8,413,891       6,280,102  
    Total operating expenses     4,846,294       3,248,681       12,828,874       8,880,138  
Operating loss     (4,387,456 )     (3,245,255 )     (10,865,276 )     (8,842,713 )
Other income (expense)     69,345       (140 )     66,549       (2,189 )
Loss before income taxes     (4,318,111 )     (3,245,395 )     (10,798,727 )     (8,844,902 )
Income taxes     -       -       -       -  
Net loss   $ (4,318,111 )   $ (3,245,395 )   $ (10,798,727 )   $ (8,844,902 )
Loss per common share - basic and diluted   $ (0.15 )   $ (0.13 )   $ (0.39 )   $ (0.37 )
Weighted average shares outstanding, basic & diluted     28,766,012       24,537,379       27,500,855       23,860,843  

Contact: Atossa Genetics Inc. Kyle Guse CFO and General Counsel (O) 800-351-3902 kyle.guse@atossagenetics.com Investor Relations: CorProminence LLC Scott Gordon President 516-222-2560 scottg@corprominence.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 64

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 137

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
California Stone Ban Puts a Hidden Worker Toll in View

Updated Category News Views 42

Countertops are supposed to finish a kitchen, not quietly wreck the lungs of the people cutting them. Yet California's move toward prohibiting the fabrication and installation of artificial stone containing more than 1% crystalline silica puts an ugly, long-running occupational-health problem in plain sight. This is not a story that calls for chest-thumping market talk....

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 48

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 134

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 5

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading

Top 5 Most Recently Viewed Articles

Forian Inc.'s Key Participation in ROTH MKM Annual Event

Updated Category News Views 92

Forian Inc. Engages at ROTH MKM Technology Event In a significant move within the technology sector, Forian Inc. (Nasdaq: FORA) is preparing for participation in the prestigious ROTH MKM 13th Annual Technology Event. The event promises an engaging platform for discussions surrounding technological advancements and investment opportunities. Who Will Represent Forian Inc.?...

Continue Reading
Davidson Kempner Capital Management Updates Direct Line Holdings

Updated Category News Views 202

Introduction to the Disclosure This article provides an overview of a significant disclosure regarding holdings in Direct Line Insurance Group PLC by Davidson Kempner Capital Management LP. As a major financial actor, Davidson Kempner plays a critical role in the financial ecosystem, particularly in how it approaches its investments and holdings. Key Information on...

Continue Reading
Uncovering Dropbox's Unique Marketing Strategies for Success

Updated Category News Views 360

Drew Houston’s Key Marketing Insights Dropbox (NASDAQ: DBX) has transformed from a simple file storage service into a multibillion-dollar enterprise, largely due to the strategic marketing insights shared by CEO Drew Houston. During a notable event at Stanford University, he discussed two crucial hacks that have led to a surge of paying customers. The core idea is...

Continue Reading
22nd Century's Transformation: Debt Erased, Growth Ahead

Updated Category News Views 229

22nd Century Group Transforms with Debt-Free Balance Sheet 22nd Century Group, Inc. (NASDAQ: XXII) has made significant strides in its financial stability by completely eliminating $3.9 million in senior secured debt. This remarkable feat not only lowers their ongoing cash needs but resets the financial landscape for the company, enabling them to redirect resources...

Continue Reading
Empowering QUBT Shareholders: Your Rights and Legal Options

Updated Category News Views 170

Understanding Your Rights as a Shareholder of Quantum Computing Inc. As a shareholder of Quantum Computing Inc. (NASDAQ: QUBT), it's essential to be aware of your rights regarding the ongoing legal issue facing the company. You may have heard of a recent class action lawsuit aimed at Quantum Computing, and it's vital to understand how this could impact you as an investor....

Continue Reading